New research in JAMA Internal Medicine says many NCI-designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially." 340B groups point out that the rates are negotiated and they need the revenue for their safety net mission.

JAMA Study Finds Prominent Cancer Centers With 340B Connections Mark Up Infused Drugs Significantly

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine. Hospital groups have pointed out in the past that they mark up the drug costs to offset losses in serving large number of low-income and uninsured patients.

The study was published on April 18. It found that median price markups across 61 (out of a total of 71) NCI-designated centers studied ranged from 118% of estimated acquisition cost for sipuleucel-T to 633% for leuprolide. Both drugs are treatments for prostate cancer. According to hospital group 340B Health, 75% of NCI-designated centers have affiliated 340B hospitals.

Many National Cancer Institute (NCI) designated cancer centers—most of which are affiliated with 340B hospitals—mark up the price of infused cancer therapies for patients with private insurance “substantially,” according to new research in JAMA Internal Medicine.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report